E6/E7 mRNA expression analysis: A test for the objective assessment of cervical adenocarcinoma in clinical prognostic procedure

International Journal of Oncology

Volumn 36, Issue 6, 2010, Pages 1533-1539

  Hovland, Siri ^a   Muller, Susanne ^b   Skomedal, Hanne ^a   Mints, Michael ^c   Bergström, Jakob ^c   Wallin, Keng Ling ^b   Karlsen, Frank ^a   Johansson, Bo ^b   Andersson, Sonia ^b  

^a NorChip AS   (Norway)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Adenocarcinoma; Cervix; DNA; Human papillomavirus; mRNA; Nucleic acid sequence based amplification; Paraffin

Indexed keywords

MESSENGER RNA; PROTEIN E6; PROTEIN E7; VIRUS DNA;

ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA SEQUENCE; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA; WART VIRUS;

ADENOCARCINOMA; DNA, VIRAL; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; REPRESSOR PROTEINS; RNA, MESSENGER; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 77951545876     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000640     Document Type: Article

References (34)

1. IARC (International Agency for Research on Cancer) monographs on the evaluation of carcinogenic risks to humans. In: Human Papillomaviruses. Vol.90, Lyon, France, 2007.
2. Socialstyrelsen, Epidemiologiskt centrum Cancer incidence in Sweden, 2008.
3. Smith HO, Tiffany MF, Qualls CR and Key CR: The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States - a 24-year populationbased study. Gynecol Oncol 78: 97-105, 2000.
4. Bray F, Carstensen B, Møller H, Zappa M, Zakelj MP, Lawrence G, et al: Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 14: 2191-2199, 2005.
5. International Collaboration of Epidemiological Studies of Cervical Cancer: Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: Collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer 120: 885-891, 2006.
6. Andersson S, Rylander E, Larson B, Sigurdardottir S, Backlund I, Sällström J, et al: Types of human papillomavirus revealed in cervical adenocarcinomas after DNA sequencing. Oncol Rep 10: 175-179, 2003.
7. Meijer CJ, Snijders PJ and van den Brule AJ: Screening for cervical cancer: should we test for infection with high-risk HPV? CMAJ 163: 535-538, 2000.
8. Josefsson AM, Magnusson PK, Ylitalo N, Sorensen P, Qwarforth-Tubbin P, Andersen PK, et al: Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 355: 2189-2193, 2000. (Pubitemid 30394325)
9. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121: 621-632, 2007.
10. Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, et al: Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78: 11451-11460, 2004.
11. Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, et al: Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 314: 111-114, 1985.
12. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350, 2002.
13. Ho GY, Bierman R, Beardsley L, Chang CJ and Burk RD: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338: 423-428, 1998.
14. Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH, Fransen-Daalmeijer N, et al: Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for highrisk and lowrisk types. Int J Cancer 87: 221-227, 2000.
15. Sotlar K, Selinka HC, Menton M, Kandolf R and Bültmann B: Detection of human papillomavirus type 16 E6/E7 oncogene transcripts in dysplastic and nondysplastic cervical scrapes by nested RT-PCR. Gynecol Oncol 69: 114-121, 1998.
16. Muller S, Flores-Staino C, Skyldberg B, Hellström AC, Johansson B, Hagmar B, et al: Expression of p16INK4a and MIB-1 in relation to histopathology and HPV types in cervical adenocarcinoma. Int J Oncol 32: 333-340, 2008.
17. Andersson S, Larson B, Hjerpe A, Silfversward C, Sallstrom J, Wilander E, et al: Adenocarcinoma of the uterine cervix: the presence of human papillomavirus and the method of detection. Acta Obstet Gynecol Scand 82: 960-965, 2003.
18. Zehbe I, Evander M, Edlund K, Rylander E, Wadell G and Wilander E: Non-radioisotopic detection and typing of human papillomavirus (HPV) by use of polymerase chain reaction and single strand conformation polymorphism (PCR-SSCP). Diagn Mol Pathol 5: 206-213, 1996.
19. + PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes J. Clin Microbiol 40: 779-787, 2002.
20. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al: International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527, 2003.
21. Kraus I, Molden T, Holm R, Lie AK, Karlsen F, Kristensen GB, et al: Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33 and 45 in the majority of cervical carcinomas. J Clin Microbiol 44: 1310-1317, 2006.
22. Williams C, Ponten F, Moberg C, Soderkvist P, Uhlen M, Ponten J, et al: A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol 155: 1467-1471, 1999.
23. Tang E: Path to effective recovering of DNA from formalin-fixed biological samples in natural history collections: workshop summary. Ed. National Research Council. National Academy Press, Washington, DC, 2006.
24. Karlsen F, Kalantari M, Chitemerere M, Johansson B and Hagmar B: Modifications of human and viral deoxyribonucleic acid by formaldehyde fixation. Lab Invest 71: 604-611, 1994.
25. Clifford GM, Smith JS, Plummer N, Munoz N and Franceschi S: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88: 63-73, 2003.
26. Duggan MA, McGregor, Benoit JL, Inoue M and Stuart GCE: The human papillomavirus status of invasive cervical adenocarcinoma: A clinicopathological and outcome analysis. Hum Pathol 26: 319-325, 1995.
27. Park JS, Hwang ES, Park SN, Ahn HK, Um SJ, Kim CJ, et al: Physical status and expression of HPV genes in cervical cancers. Gynecol Oncol 65: 121-129, 1997.
28. Chung JY, Braunschweig T, Williams R, Guerrero N, Hoffmann KM, Kwon M, et al: Factors in tissue handling and processing that impact RNA obtained from formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem 56: 1033-1042, 2008.
29. McCluggage WG, Sumathi VP, McBride HA and Patterson A: A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol 21: 11-15, 2002.
30. Castrillon DH, Lee KR and Nucci MR: Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol 21: 4-10, 2002.
31. Zielinski GD, Snijders PJ, Rozendaal L, Daalmeijer NF, Risse EK, Voorhorst FJ, et al: The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol 201: 535-543, 2003.
32. Ylitalo N, Sorensen P, Josefsson AM, Magnusson PK, Andersen PK, Ponten J, et al: Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 355: 2194-2198, 2000. (Pubitemid 30394326)
33. Wang JL, Zheng BY, Li XD, Angström T, Lindström MS and Wallin KL: Predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer. Clin Cancer Res 10: 2407-2414, 2004.
34. Khleif SN, DeGregori J, Yee CL, Otterson GA, Kaye FJ, Nevins JR, et al: Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA 93: 4350-4354, 1996.